Why the study?
Does weekly paclitaxel provide clinical benefit in patients with unresectable angiosarcoma?
Does weekly paclitaxel provide clinical benefit in patients with unresectable angiosarcoma?
Weekly paclitaxel demonstrates clinical benefit and is well tolerated in unresectable angiosarcoma.
May support paclitaxel in unresectable angiosarcoma; leaves open randomized confirmation of benefit.
Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit.
No takes yet. Share an insight, caveat, or question.
Penel et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: